AnaptysBio Inc

NASDAQ:ANABUnited States

Nov 5, 2024

Show headlines and story abstract

• Anaptys Announces Participation in November and December Investor Conferences, from 4:15PM ET on Tuesday Nov 05, 2024 by Dow Jones

  4:15PM ET on Tuesday Nov 05, 2024 by Dow Jones
  Companies Mentioned: ANAB
  
  Anaptys Announces Participation in November and December Investor Conferences
  
  SAN DIEGO, Nov. 05, 2024 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that Daniel Faga, president and chief executive officer of Anaptys, and/or other members of its senior management team, are scheduled to participate in multiple upcoming investor conferences:
  

• Anaptys Announces Third Quarter 2024 Financial Results and Provides Business Update, from 4:15PM ET on Tuesday Nov 05, 2024 by Dow Jones

  4:15PM ET on Tuesday Nov 05, 2024 by Dow Jones
  Companies Mentioned: ANAB
  
  GSK4069889). To learn more, visit www.AnaptysBio.com or follow us on LinkedIn and X.
  
  Forward-Looking Statements
  
  This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to: the timing of the release of data from the Company's clinical trials, including ANB032's Phase 2b clinical trial in atopic dermatitis, and rosnilimab's Phase 2b clinical trial in rheumatoid arthritis and Phase 2 clinical trial in ulcerative colitis; the timing of initiation of ANB101's Phase 1 clinical trial; the timing of disclosure of the Phase 1b indication for ANB033; the potential to receive any additional royalties from the GSK collaboration; the Company's ability to find a licensing partner for imsidolimab or etokimab and the timing of any such transaction; and the Company's projected cash runway. Statements including words such as "plan," "intend," "continue," "expect," or "ongoing" and statements in the future tense are forward-looking statements. These forward-looking statements involve risks and uncertainties, as well as assumptions, which, if they do not fully materialize or prove incorrect, could cause its results to differ materially from those expressed or implied by such forward-looking statements. Forward-looking statements are subject to risks and uncertainties that may cause the company's actual activities or results to differ significantly from those expressed in any forward-looking statement, including risks and uncertainties related to the company's ability to advance its product candidates, obtain regulatory approval of and ultimately commercialize its product candidates, the timing and results of preclinical and clinical trials, the company's ability to fund development activities and achieve development goals, the company's ability to protect intellectual property and other risks and uncertainties described under the heading "Risk Factors" in documents the company files from time to time with the Securities and Exchange Commission. These forward-looking statements speak only as of the date of this press release, and the company undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date hereof.
  

• *DJ AnaptysBio 3Q Loss $32.9M >ANAB, from 4:15PM ET on Tuesday Nov 05, 2024 by Dow Jones

  4:15PM ET on Tuesday Nov 05, 2024 by Dow Jones
  Companies Mentioned: ANAB